bioRxivBiophysicsPreprint
Imipramine binds to Amyloid-beta(1-42) monomers in vitro, as shown by NMR spectroscopy.
James Beham, Noah R. JohnsoniD, Beat VögeliiD, Morkos A. HeneniD, Liliya VugmeysteriD
Abstract
Imipramine is known as an older generation tricyclic antidepressant drug. It has been identified in prior studies that imipramine blocks Apolipoprotein E4 (ApoE4)-induced amyloid-{beta}(A{beta}) aggregation and is associated with an improved AD diagnosis [Johnson et al. Alzheimers Research Therapy, 2022, 14, 88]. Using NMR methods such as 1H-1H NOESY and Saturation Transfer Difference Spectroscopy, we demonstrate the binding of A{beta} monomers to imipramine when the full-length A{beta} (1-42) sequence is considered. The more abundant but less toxic form, A{beta} (1-40) does not show interaction with imipramine.
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Imipramine binds to amyloid-β and extends the survival of Alzheimer's disease patients
Noah R. Johnson, James Beham, … Huntington Potter·bioRxiv·Nov 3, 2026
- Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition
Noah R. Johnson, Athena C.-J. Wang, … Huntington Potter·bioRxiv·Mar 28, 2021
- Naphthalene monoimide derivative ameliorates amyloid burden and cognitive decline in a transgenic mouse model of Alzheimer's disease
Sourav Samanta, Kolla Rajasekhar, … Thimmaiah Govindaraju·Advanced TherapeuticsPeer-reviewed·Jan 28, 2021
- Impairment of brain function in a mouse model of Alzheimer's disease during the pre-depositing phase: the role of alpha7 nicotinic acetylcholine receptors
Olena Lykhmus, Wen-Yu Tzeng, … Maryna V. Skok·Biomedicine & PharmacotherapyPeer-reviewed·Aug 7, 2024
- Distinct Filament Conformation for Receptor-Bound Amyloid-β from Alzheimers Disease Brain
Mikhail A. Kostylev, Carmen Butan, … Stephen M. Strittmatter·Nature CommunicationsPeer-reviewed·Jul 22, 2026
- Metabolic resistance of Abeta3pE-42, epitope of the anti-Alzheimer therapeutic antibody, donanemab.
Nobuhisa Iwata, Satoshi Tsubuki, … Takaomi C. Saido·Life Science AlliancePeer-reviewed·Sep 30, 2024